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Abstract
Background: Recognition of health disparities in Clostridium difficile infection (CDI) is an initial step toward
improved resource utilization and patient health. The purpose of this study was to identify health disparities by
black vs. white race among hospitalized adults with CDI in the United States (U.S.) over 10 years.
Methods: This was a retrospective analysis of the U.S. National Hospital Discharge Surveys from 2001 to 2010.
Eligible cases included adults with an ICD-9-CM code for CDI (008.45). Patients with missing race or “other race”
were excluded. The primary outcome, CDI incidence, was calculated as CDI discharges per 1,000 total discharges.
Data weights were used to determine national estimates. Secondary outcomes included in-hospital mortality,
hospital length of stay (LOS), and severe CDI. Comparisons were made using bivariable analyses. Race was assessed
as an independent risk factor for CDI outcomes using logistic regression or proportional hazards models.
Results: These data represent 1.7 million CDI discharges, where 90 % of patients were identified as white and 10 %
black. Blacks differed from whites with respect to all baseline characteristics (p <0.0001). CDI incidence was significantly
higher in whites compared to blacks (7.7/1,000 discharges vs. 4.9/1,000 discharges, p < 0.0001). Blacks had higher
mortality (7.4 % vs. 7.2 %, p < 0.0001), LOS >7 days (57 % vs. 52 %, p < 0.0001), and severe CDI (24 % vs. 19 %, p < 0.
0001). In multivariable analyses, black race was a positive predictor of mortality (OR 1.12, 95 % CI 1.09–1.15) and severe
CDI (OR 1.09, 95 % CI 1.07–1.11), and negative predictor for hospital LOS (OR 0.93, 95 % CI 0.93–0.94).
Conclusions: CDI incidence was higher for white patients; however, black race was independently associated with
mortality and severe CDI.
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Abbreviations: AHRQ, Agency for healthcare research and quality; aOR, Adjusted odds ratio; CDI, Clostridium difficile
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ICD-9-CM, International classification of diseases, 9th rev, clinical modification; LOS, Length of stay; NHDS, National
hospital discharge survey; TLR2, Toll-like receptor 2; US, United States; VIF, Variance inflation factor
Background
Efforts are being made to eliminate health disparities in
the United States (U.S.); however, disparities due to race,
ethnicity, geographics, and socioeconomics continue to
exist [1–4]. Prior studies have reported reduced access
to primary healthcare services among minority patients,
potentiating the likelihood of suboptimal patient out-
comes [5–8]. Infectious diseases are the second-leading
contributor to racial disparities in healthcare after car-
diovascular disease [9]. Health disparities have been spe-
cifically reported in infectious diseases, though studies
are limited. Compared to white patients, black patients
have an increased incidence and severity of sepsis and
receive a lower quality of care for severe infections
[10–12]. Few studies have examined the impact of
disparities on other infections, such as Clostridium
difficile infection (CDI) [3, 13].
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CDI is a common infection with increasing incidence
in U.S. hospitals as well as the community [14, 15].
Symptoms of infection range from mild, uncomplicated
diarrhea to more severe manifestations with complica-
tions including sepsis, renal failure, ileus, toxic megaco-
lon, perforated intestine, or death [16–18]. The
incidence of and outcomes from CDI might differ by
race due to factors that influence the gastrointestinal
microbiome, such as medications and diet, and socioeco-
nomic factors, including insurance status and access to
care. While research suggests black patients are less
likely to receive broad-spectrum antibiotics, they are
more likely to have a longer admission to a hospital
emergency department and have higher rates of hospital
readmission, which could impact patient health out-
comes [19–22]. Despite these associations, few studies
have evaluated racial health disparities in CDI.
Recognition of health disparities in CDI is an initial
step towards more targeted resource utilization and im-
proved patient health. The goal of this study was to
identify health disparities by black vs. white race in CDI
incidence and health outcomes among hospitalized
adults with CDI in the U.S. over a 10-year period.
Methods
Data source
This study utilized data from the Centers for Disease
Control and Prevention’s National Hospital Discharge
Survey (NHDS). The NHDS is a national probability
sample of non-federal, short-stay hospital discharges in
the U.S. A complex, three-stage sampling methodology
allows the user to apply data weights to derive national
estimates representative of the U.S. population [23].
The survey data include patient demographics, such as
age, gender, self-reported race, and marital status, as well
as year of discharge, payment sources, geographic region,
hospital length of stay (LOS), and hospital discharge sta-
tus. Diagnoses and procedures are also reported as Inter-
national Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) codes. NHDS data have pre-
viously been used in several infectious diseases epi-
demiological studies, including healthcare-associated
infections [14, 24, 25].
Study design
This was a retrospective analysis of all patients dis-
charged from U.S. hospitals from 2001 to 2010. Eligible
cases included adults at least 18 years of age with a prin-
cipal or secondary ICD-9-CM discharge diagnosis code
for CDI (008.45). Patients with missing race or “other
race” were excluded.
Patient baseline characteristics were classified based
on the categories provided in the NHDS for patient sex,
hospital size (6–99 beds, 100–199 beds, 200–299 beds,
300–499 beds, or ≥500 beds), hospital ownership (pro-
prietary, government, or nonprofit), and admission type
(emergency, urgent, or elective). Other patient character-
istics were classified by limited definitions designed to
encompass NHDS categories: race (white, black, and
other), expected primary source of payment (private,
Medicare, Medicaid, self-pay, and other), and admission
source (emergency room, transfer, referral, and other).
Health outcomes in this study included in-hospital
mortality, hospital LOS, and any severe CDI. The
“Discharge Status” item of the NHDS was used to deter-
mine patient mortality. This represents all-cause, in-
hospital mortality for patients with CDI. Hospital LOS
was extracted from the “Days of Care” item of the
NHDS and was presented as medians (interquartile
ranges). In this study, severe CDI was indicated by cases
with a principal or secondary ICD-9-CM code for at
least one of the following: septicemia (038.x), septic
shock (785.52), acute renal failure (584.x), toxic megaco-
lon (558.2), prolonged ileus (560.1), perforated intestine
(569.83), or colectomy (45.7x).
Statistical analyses
First, baseline patient demographics were summarized
using medians (interquartile ranges) for continuous vari-
ables and counts (percentages) for categorical variables.
All baseline characteristics were assessed for multicolli-
nearity using the Spearman rank correlation. Correlation
coefficients were then converted to variance inflation
factors (VIF) using the following equation: VIF = 1/(1-
R2). Two variables were considered highly correlated if
they had a VIF >10 and were statistically significant at
an alpha <0.0001. We compared baseline characteristics
between races using bivariable analyses calculated using
the chi-square test for categorical variables and Wil-
coxon rank-sum test for continuous variables. Next, we
determined the overall CDI incidence rate using CDI
discharges as the numerator, as identified in our cohort,
and total discharges as the denominator. Total dis-
charges were derived from the composite NHDS data,
which include all CDI and non-CDI patients. Incidence
by race was calculated as CDI discharges per race cat-
egory divided by total discharges per race category. Data
weights were applied to derive national estimates and in-
cidence rates were presented as CDI discharges per
1,000 total discharges.
CDI incidence, patient mortality, hospital LOS, and se-
vere CDI were characterized overall and by race. CDI in-
cidence was compared by race using the z-test. Health
outcomes were compared using the chi-square or
Wilcoxon rank sum test. Risk for CDI health outcomes
was analyzed using multivariable logistic regression to
calculate adjusted odds ratios (aOR) and 95 % confi-
dence intervals (CI) for mortality and any severe CDI
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using white race as the reference category. A Cox pro-
portional hazards model was used to calculate the aOR
and 95 % CI for hospital LOS, which allowed us to cen-
sor those CDI patients who died in the hospital. The re-
gression models controlled for patient-specific variables,
including age ≥65 years, sex, geographic region, hospital
size, hospital ownership, other infectious diseases as in-
dicated by ICD-9-CM codes (skin infection, pneumonia,
bacteremia, device-related infections, urinary tract infec-
tion, and endocarditis), principal or secondary CDI diag-
nosis, other common principal diagnoses (e.g., cancer,
congestive heart failure, chronic obstructive pulmonary
disease [COPD], myocardial infarction, diabetes, cere-
brovascular disease, and human immunodeficiency dis-
ease [HIV]), principal payment source, admission type,
and admission source. The mortality and hospital LOS
models also included severe CDI as a covariate. Statis-
tical significance was indicated by p < 0.0001 due to the
large sample size provided by the NHDS. JMP 10.0®




The patient baseline characteristics are provided in
Table 1. Overall, these data represent approximately 1.7
million CDI discharges from U.S. hospitals over the
study period. Of these patients, 90 % were white and
10 % were black. Approximately 500,000 patients were
excluded because of a missing race code or classification
as “other race.” Overall, patients were predominately fe-
male (59 %) and at least 65 years old (71 %). Black and
white patients with CDI significantly differed with re-
spect to patient age, sex, geographic region, hospital size
and ownership, principal payment source, admission
type and source, and principal diagnoses. White patients
were a median (interquartile range) 76 (63–83) years of
age, while black patients were much younger [65 (50–78)
years]. Black patients were more likely than white patients
to be discharged from a hospital with over 500 beds (25 %
and 11 %, respectively), and were more likely to have
Medicaid as their principal payment source (17 % and
5 %, respectively). Additionally, black patients were also
more likely to have an emergent admission type (78 % and
65 %, respectively). No baseline characteristics had a VIF
>2, indicating low multicollinearity among variables.
CDI incidence
The overall CDI incidence was 7.3 CDI discharges per
1,000 total discharges. CDI incidence was significantly
higher for white patients (7.7 CDI discharges per 1,000
white discharges) as compared to black patients (4.9
CDI discharges per 1,000 black discharges) (p < 0.0001).
From 2001 to 2010, the incidence of CDI in black and
white patients increased (Fig. 1). The incidence was
highest in 2009 for white patients (9.6 CDI discharges
per 1,000 white discharges), and highest in 2008 for
black patients (6.7 CDI discharges per 1,000 black
discharges).
Health outcomes
Health outcomes are depicted in Table 2. The median
(interquartile range) hospital LOS for all hospitalized pa-
tients with CDI was 8 (5–14) days and all-cause, in-
hospital mortality was 7.3 %. Hospital LOS and mortality
were significantly higher for black patients (9 days and
7.4 %, respectively) as compared to white patients (8 days
and 7.2 %, respectively) (p < 0.0001 for each comparison).
Black race was an independent risk factor for all health
outcomes. Compared to white patients, black patients
had significantly greater mortality (aOR 1.12, 95 % CI
1.09–1.15, p < 0.0001) and were at significantly greater
risk for severe CDI (aOR 1.09, 95 % CI 1.07–1.11, p <
0.0001). Other significant predictors of mortality in-
cluded: age ≥ 65 years (aOR 2.67, 95 % CI 2.60–2.75), fe-
male sex (aOR 1.08, 95 % CI 1.06–1.10), urinary tract
infection (aOR 1.36, 95 % CI 1.35–1.37), sepsis (aOR
3.54, 95 % CI 3.47–3.60), and any severe CDI (aOR 2.12,
95 % CI 2.08–2.16). Other significant predictors of se-
vere CDI included: age ≥ 65 years (aOR 1.39, 95 % CI
1.37–1.41), private hospital admission (aOR 1.61, 95 %
CI 1.57–1.65), urinary tract infection (aOR 1.36, 95 % CI
1.35–1.37), and emergency admission (aOR 1.53, 95 %
CI 1.51–1.55). After censoring for inpatient mortality,
black patients had a significantly shorter hospital LOS
compared to white patients (aOR 0.94, 95 % CI 0.93–
0.94, p < 0.0001).
Discussion
In this retrospective cohort study of approximately 1.7
million hospital discharges, we identified disparities in
CDI incidence and health outcomes by race. Remark-
ably, CDI incidence among white patients was 57 %
greater than that of black patients. As CDI rates con-
tinue to increase and gaps in patient access to care con-
tinue to narrow, this disparity may change. Importantly,
CDI mortality and severity were significantly worse for
black patients. To our knowledge, this is the first study
to find that black race is associated with poorer health
outcomes in CDI. Because of the small absolute differ-
ences in mortality and severity rates between white and
black CDI patients, the clinical significance of our findings
is unknown, but is worth addressing in future studies due
to the high cost burden associated with CDI [15].
Knowledge of healthcare disparities can be used to tar-
get resource utilization to improve patient health out-
comes and eliminate disparities in the future [4].
Disparities attributed to race have been reported with
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respect to primary care access, as well as in surgery, sep-
sis, and pneumonia [5–8, 10–12, 26]. However, little re-
search has focused on disparities associated with
healthcare-associated infections [13]. Our study adds to
the few prior studies examining the occurrence and re-
currence of CDI where race was assessed as an inde-
pendent risk factor [13, 27, 28]. In 2012, Murphy et al.
published the first study to note that race and ethnicity
were predictive of CDI [27]. One year later, Freedberg et
al. incidentally found a higher risk of recurrent CDI in
black patients in a study designed to assess the risk of
CDI recurrence associated with proton pump inhibitors
[28]. More recently, Bakullari et al. demonstrated signifi-
cant racial and ethnic disparities in the rate of occur-
rence of healthcare-associated infections [13]. While the
study did not find a statistically significant difference in
the rate of CDI between white and black patients, it ex-
amined a much smaller population using the Medicare
Patient Safety Monitoring System.
The reason for such disparities in incidence and out-
comes in CDI is likely multifactorial. Among patients
with CDI, black patients significantly differed from white
patients with respect to all patient demographics. For
example, black patients with CDI were younger than
white patients and had greater use of Medicaid as a prin-
cipal payment source. Considering older age is a known
risk factor for CDI, the younger age of black CDI pa-
tients could have contributed to the lower CDI incidence
seen for blacks in this study [15, 17]. Older age is associ-
ated with more comorbidities and health care exposures,
which could increase for the risk for CDI as well as in-
crease the likelihood for early diagnosis. The significant
differences in principal payment source in our study are
also likely a reflection of the younger age of the black
population with CDI, as compared to the typical elderly
CDI population, which relied heavily on Medicare.
While this study was unable to assess for relationships
between all co-morbid conditions and racial differences
in CDI, the chronic, co-morbid conditions disparately af-
fecting blacks may also increase the risk for CDI and
predispose this population to overall poorer health out-
comes [10]. Furthermore, disparity research suggests the










75 (61–83) 76 (63–83) 65 (50–78) <0.0001
Age ≥65 years, % 71 73 50 <0.0001
Female sex, % 59 59 58 <0.0001
Geographic region, % <0.0001
Northeast 32 33 28
Midwest 18 18 15
South 37 35 49
West 13 14 8
Hospital size, % <0.0001
6–99 beds 20 21 12
100–199 beds 23 24 11
200–299 beds 23 23 21
300–499 beds 21 21 31
500+ beds 13 11 25
Hospital ownership, % <0.0001
Proprietary 14 15 11
Government 10 9 15
Nonprofit 76 76 74
Principal payment source, % <0.0001
Medicare 69 71 58
Medicaid 6 5 17
Private 21 21 19
Self-pay 2 1 3
Other 2 2 3
Admission type, % <0.0001
Emergency 67 65 78
Urgent 20 21 16
Elective 13 14 6




Transfer 16 16 13
Referral 17 17 14
Other 8 8 6




32 32 31 <0.0001
Pneumonia 4 5 3 <0.0001
Urinary tract
infection
3 2 5 <0.0001
Cancer 3 3 3 <0.0001
Congestive
heart failure
2 2 2 <0.0001
COPD 2 2 1 <0.0001
Table 1 Baseline characteristics (Continued)
Myocardial
infarction
1 1 1 0.0294
Diabetes 1 1 2 <0.0001
Cerebrovascular
disease
1 1 2 <0.0001
HIV <1 <1 2 <0.0001
IQR interquartile range, COPD chronic obstructive pulmonary disease, HIV
human inmmunodeficiency virus
aP-values reflect comparisons between white and black patients
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most effective resource use would aim at eliminating the
top racial disparities, including hypertension, diabetes,
and HIV [9, 10].
Factors such as health insurance, access to care, quality
of care, or health-related behavior may also contribute to
this disparity [9]. According to the U.S. Census Bureau in
2012, 40.6 % of blacks relied on Medicaid or other
publicly-funded insurance compared to 29.3 % of non-
Hispanic whites [29]. Additionally, 17.2 % of blacks were
uninsured compared to 10.4 % of non-Hispanic whites
[29]. Furthermore, black patients are more likely to seek
care at higher-volume hospitals than white patients and
often receive care at hospitals providing a lower quality of
care [12, 26, 30]. According to the Agency for Healthcare
Research and Quality (AHRQ) in 2010, black patients had
worse access to care than white patients for one-third of
core measures and were less likely to have a specific
source of ongoing care (84.7 % and 86.3 %, respectively)
[31]. Decreased access to care could explain the signifi-
cantly increased rate of hospital admissions via emergency
department for the black population seen in our study.
Differences in medication use might also contribute to
CDI disparities. White patients are more likely to receive
prescription antibiotics, broad-spectrum antibiotics, and
proton pump inhibitors, putting them at greater risk for
disruption of the normal gastrointestinal flora, likely
contributing to differential CDI incidence [19, 20, 28].
Surveys have also shown that white patients are more
accepting of new prescription drugs than blacks [32].
Considering race is more relevant as a social construct
than a biological construct in the United States, it is un-
likely the disparities noted here are due to genetic differ-
ences in the population; however, this cannot be ruled out
[33–35]. A previous study by Esper et al. suggested a gen-
etic polymorphism in black patients in the human Toll-like
receptor 2 (TLR2) could directly create a race-specific alter-
ation in host response to Gram-positive pathogens [10].
Distribution differences in the polymorphic functional allele
were previously found between African Americans and
Caucasians, and given differential TLR2 promoter activity
in response to interferon-gamma, contrastive pathogenesis
of Gram-positive infectious organisms is possible between
Fig. 1 Clostridium difficile infection (CDI) incidence per year for white and black patients, 2001–2010
Table 2 Health outcomes
Outcome Overall (n = 1,676,903) White (n = 1,503,189) Black (n = 173,714) P-Valuea
CDI incidence 7.3 7.7 4.9 <0.0001
Mortality, % 7.3 7.2 7.4 <0.0001
Hospital LOS, median (IQR) 8 (5–14) 8 (4–14) 9 (5–16) <0.0001
Hospital LOS >7 days, % 52 52 57 <0.0001
Any severe CDI,b % 20 19 24 <0.0001
Sepsis 13 12 16
Renal failure 16 15 21
CDI Clostridium difficile infection, IQR interquartile range, LOS length of stay
aP-values reflect comparisons between white and black patients
bPercentages not shown for severe CDI outcomes present in <5 % of the population (shock, megacolon, ileus, perforated intestine, and colectomy)
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races [36]. Considering Clostridium difficile is a Gram-
positive bacterium, this may warrant further research.
This study has potential limitations. First, this study
relied on administrative data using ICD-9-CM coding to
identify CDI and other diagnoses; therefore, it may not
fully capture all CDI cases. A prior study evaluating the
use of the ICD-9-CM code to identify CDI found high
sensitivity (78 %) and specificity (99.7 %) compared to
microbiological data [37]. This study design also pre-
cluded us from assessing other markers of disease sever-
ity, such as the McCabe or Charlson Comorbidity
scores. Additionally, race was self-reported and may not
accurately represent the patient population. The exclu-
sion of patients with missing race or “other race” could
limit the generalizability of the results. The NHDS
excludes federal hospitals and long-term care hospitals,
potentially limiting the application of our results to
those patient populations. Data regarding patient ethni-
city, socioeconomic status, treatment(s), prior medica-
tion(s), care access, and other patient demographics
were unavailable for this study. The lack of control for
these factors may have influenced results. Future studies
evaluating CDI disparities should consider health insurance
status or funding source, education level, medication and
disease history, as well as health-related behavior issues in
order to evaluate the broader scope of the problem.
Conclusions
Despite the higher incidence of CDI among white pa-
tients, black patients had significantly higher mortality
and risk for severe CDI compared to white patients. Fur-
ther studies are needed to provide insights into the basis
for this observation. Knowledge of existing health dispar-
ities can be used to better direct resources and improve
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